PT-141 10MG
-
Detail
Research Peptide · For Laboratory Use Only
PT-141 (Bremelanotide) 10mg
Melanocortin Receptor Agonist · Cyclic Heptapeptide · Lyophilized Powder · Purity ≥99% (HPLC)
PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide agonist of melanocortin receptors (MC1R, MC3R, MC4R and MC5R), with its primary pharmacological activity attributed to MC4R activation in the central nervous system. Its sequence — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ — was derived from the melanocortin analog research lineage of Melanotan II, engineered for metabolic stability and potent receptor binding.
Unlike peripherally acting compounds, PT-141 acts centrally on melanocortin pathways in the hypothalamus, which made it a landmark molecule in sexual arousal research: the approved drug Vyleesi® (bremelanotide) became the first FDA-approved peptide in its therapeutic class for hypoactive sexual desire disorder in premenopausal women. Each vial is supplied as a sterile lyophilized (freeze-dried) powder to ensure maximum stability.
Product Specifications
Product Name PT-141 (Bremelanotide) CAS Number 189691-06-3 (free base) Amino Acid Sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ (cyclic heptapeptide containing the non-standard amino acid norleucine (Nle) and a D-Phe residue; macrocyclized through the Asp–Lys side chains) Molecular Formula C₅₀H₆₈N₁₄O₁₀ Molecular Weight 1025.16 g/mol (free base) Receptor Profile MC1R / MC3R / MC4R / MC5R agonist (primary activity at MC4R) Quantity 10mg per vial Physical Form White to off-white lyophilized powder Purity ≥99% as determined by HPLC Storage -20°C for long term; 2–8°C for short term (lyophilized) What is PT-141?
The melanocortin system — centered on α-melanocyte-stimulating hormone (α-MSH) and its receptors — regulates a remarkable spectrum of physiology: pigmentation, energy homeostasis, inflammation, and sexual arousal. PT-141 emerged from the same medicinal chemistry lineage as the tanning research peptide Melanotan II, when investigators noticed that systemic melanocortin activation reliably produced arousal responses in animal models.
PT-141 was designed to capture this central arousal effect in a metabolically stable, high-affinity cyclic peptide. Its key structural features include:
- Norleucine (Nle) replacing methionine, improving oxidative stability;
- D-Phe at the core pharmacophore position, enhancing receptor affinity and enzymatic resistance;
- A macrocyclic lactam bridge (Asp–Lys side-chain cyclization) that locks the peptide into its bioactive conformation.
In published research, PT-141 has been investigated in a wide range of settings, including:
- Sexual arousal and desire research — clinical trials supported FDA approval of bremelanotide (Vyleesi®) in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women;
- Male erectile function studies, where central melanocortin activation was shown to induce responses through brain and spinal pathways, mechanistically distinct from peripheral vasodilators;
- MC4R pharmacology in energy homeostasis and appetite research;
- Anti-inflammatory and neuroprotective studies, where melanocortin agonists have shown immunomodulatory effects in animal models.
As the first FDA-approved melanocortin-based peptide for sexual arousal disorder, bremelanotide has made PT-141 one of the most clinically documented compounds in the melanocortin research field — a reference molecule for central arousal pathway studies.
Mechanism of Action
Handling & Storage Guidelines
- Lyophilized powder: Store at -20°C for long-term stability; 2–8°C is acceptable for short-term storage. Avoid repeated temperature cycling and protect from light and moisture.
- Before opening: Allow the vial to reach room temperature and briefly centrifuge to ensure the full contents collect at the bottom of the vial.
- Reconstitution: Add bacteriostatic water or an appropriate solvent gently along the vial wall. Swirl slowly until fully dissolved; avoid vigorous shaking. The cyclic structure gives PT-141 good stability, but gentle handling preserves integrity.
- Reconstituted solution: Store at 2–8°C and use promptly; do not refreeze the solution.
- General: Handle with standard laboratory protective equipment (gloves, lab coat, eye protection).
Why Choose Our PT-141?
🧪
Verified Purity
Each batch tested by HPLC & MS; COA available upon request.
📦
Secure Packaging
Sealed vials with temperature-protective packaging for safe delivery.
🚚
Fast Dispatch
Orders processed promptly with tracking provided.
Frequently Asked Questions
Q1: Is PT-141 the same as Bremelanotide?
A: Yes. PT-141 is the original development code; Bremelanotide is the same molecule's international nonproprietary name (INN), marketed as Vyleesi® for HSDD in premenopausal women.
Q2: How does PT-141 differ from Melanotan II?
A: Both derive from the same melanocortin analog lineage and share a closely related cyclic core, but they differ in research focus: Melanotan II is studied mainly for pigmentation (MC1R-driven melanogenesis), while PT-141 was developed specifically for central arousal effects (MC4R-driven), without the tanning emphasis.
Q3: How does PT-141 differ from PDE5 inhibitors such as sildenafil-type compounds?
A: The mechanisms are fundamentally different. PDE5 inhibitors act peripherally on vascular smooth muscle to enhance blood flow, while PT-141 acts centrally on melanocortin receptors in the brain and spinal cord, modulating the arousal signal itself. The two mechanisms are complementary rather than interchangeable.
Q4: How should I store it after receiving?
A: Keep unopened vials at -20°C for long-term storage. Once reconstituted, refrigerate at 2–8°C and use promptly; do not refreeze the solution.
Q5: Is a Certificate of Analysis (COA) available?
A: Yes, third-party tested COA documentation can be provided for each batch. Please contact our customer service with your order number.
⚠ Research Use Only — Disclaimer
All product information provided on this page is solely for information dissemination and educational purposes. The products offered are intended exclusively for in vitro laboratory research and are not pharmaceuticals. They have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for the purposes sold here, and must not be used to prevent, treat or cure any medical condition, disease or ailment.
It is strictly prohibited to introduce these products into the human or animal body in any form. By purchasing, the buyer acknowledges full responsibility for the proper handling, use and compliance with all applicable local laws and regulations.
-
Customer ReviewsNo comments